All News

The investigational oral, selective NaV1.8 pain signal inhibitor from Vertex Pharmaceuticals demonstrated a favorable benefit/risk profile in 3 phase 3 trials.

Researchers aimed to address the change in trust individuals exhibited regarding US physicians and hospitals during the COVID-19 pandemic.

Catch up on important diabetes news from the month of July.

Catch up on important pain management news from the month of July.

CVS Caremark and the State of Illinois settled a lawsuit due to the company’s failure to pay contracted rebates.

The new FDA-approved presentation will be the company’s third 505(b)(2) injectable added in 2024, expected to launch in the third quarter.

Catch up on important dermatology news from the month of July.

Researchers analyzed the prominence of opioid and methadone prescriptions for hospitalized newborns with substantial morbidities.

Check out this list of our top 10 most read stories from July 2024.

A roundtable session discussed the real-world implications of applying Direct and Indirect Remuneration (DIR) fees at the point of sale rather than through retroactive clawback.

In case you missed it, this week we had news about drug expenditures, managing the peak asthma season, successes in HIV drugs, and more.

Check out these important FDA updates from the month of July 2024.

Researchers aimed to address the associations between prenatal cannabis use and maternal health outcomes over a 9-year period.

Galderma said the FDA has accepted the company’s Biologics License Application for the therapy based on data from the trials.

In the final part of his conversation on Over the Counter, Mayank Amin, PharmD, RPh, MBA, reflects on 5-years worth of learnings at Skippack Pharmacy and offers candid perspectives on the future of community pharmacy.

In part 3 of his conversation with Drug Topics on Over the Counter, Mayank Amin, PharmD, RPh, MBA, continues his inspiring story of reopening Skippack Pharmacy and details the beginnings of The Superman Pharmacist.

Check out these featured Drug Topics interviews from July 2024.

Full efficacy and safety results for the phase 3 PURPOSE 1 trial were announced by Gilead at AIDS 2024.

In a House Committee on Oversight and Accountability hearing, Democrats and Republicans took a bipartisan stance to question the role major PBMs play regarding rising drug costs in the US.

PASO DOBLE is the largest head-to-head, phase 4 randomized clinical trial comparing DTG/3TC and BIC/FTC/TAF in patients with HIV.

From 2021 to 2022, the prevalence of adults with diabetes who used cannabis increased by 33.7%.

A survey conducted by Surescripts, a health care solutions company, explored the attitudes of pharmacists and prescribers towards ongoing issues and challenges currently facing the industry.

In part 2 of his interview with Drug Topics featured on Over the Counter, Mayank Amin, PharmD, RPh, MBA, discusses how he redefined the role of a pharmacy at Skippack Pharmacy.

In part 1 of a recent conversation on Over the Counter, Mayank Amin, PharmD, RPh, MBA, shared his journey from pharmacy school to pharmacy ownership.

MK-1654 (clesrovimab) met its primary efficacy endpoint of incidence of patients with RSV-associated medically attended lower respiratory infections (MALRI) through Day 150.

Industry experts explored the increase in US prescription drug spending and how state spending targets come into play regarding patients’ rising out-of-pocket costs.

Check out important updates from the FDA from over the past week.

The most common adverse events in patients using oral corticosteroids for more than 90 days included fracture, hyperlipidemia, myocardial infarction, and avascular necrosis.